The relationship between cervical precancerous lesion galectin-3 and p27 protein expression and clinical prognosis

Ma,Jianting; Zhang,Xingguang; He,Gang; Yang,Chunlin

doi:10.3892/ol.2017.7503

The relationship between cervical precancerous lesion galectin-3 and p27 protein expression and clinical prognosis

Authors:
- Jianting Ma
- Xingguang Zhang
- Gang He
- Chunlin Yang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Yuyao People's Hospital, Yuyao, Zhejiang 315400, P.R. China
Published online on: November 29, 2017 https://doi.org/10.3892/ol.2017.7503
Pages: 1533-1536
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The relationship between galectin-3 and p27kip1 protein expression levels in cervical precancerous lesions and clinical prognosis were studied. A total of 74 patients with cervical intraepithelial neoplasia [(CIN), 20 cases classified as stage I, 24 cases as stage II and 30 cases as stage III] were enrolled in this study. Tissue galectin-3, p27kip1, vascular endothelial growth factor (VEGF)-2 and cyclin D protein levels were detected via immunohistochemical staining and reverse transcription polymerase chain reaction (PCR). Follow-up median duration was 13.5 months and recurrence rate was determined. Galectin-3, VEGF-2, and cyclin D expression was elevated in patients with higher stage CIN, whereas p27kip1 showed the opposite trend (p<0.05). During follow-up, there were 3 cases (15.0%) of recurrence in the CIN-I group, 5 cases (20.8%) in the CIN-II group and 9 cases (30.0%) in CIN-III the group. No significant difference in recurrence rate was noted among the groups (p>0.05). The upregulation of galectin-3 and downregulation of p27kip1 in CIN tissues may be related to tumor progression. This phenomenon will require further verification.

View Figures

View References

1	Xu XX, Zhou JS, Yuan SH, Yu H and Lou HM: Distribution of HPV genotype in invasive cervical carcinoma and cervical intraepithelial neoplasia in Zhejiang province, Southeast China: Establishing the baseline for surveillance. Int J Environ Res Public Health. 12:10794–10805. 2015. View Article : Google Scholar : PubMed/NCBI
2	Magaldi TG, Almstead LL, Bellone S, Prevatt EG, Santin AD and DiMaio D: Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation. Virology. 422:114–124. 2012. View Article : Google Scholar : PubMed/NCBI
3	Than NG, Romero R, Balogh A, Karpati E, Mastrolia SA, Staretz-Chacham O, Hahn S, Erez O, Papp Z and Kim CJ: Galectins: Double-edged swords in the cross-roads of pregnancy complications and female reproductive tract inflammation and neoplasia. J Pathol Transl Med. 49:181–208. 2015. View Article : Google Scholar : PubMed/NCBI
4	Yu H, Zhang S, Zhang R and Zhang L: The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma. J Exp Clin Cancer Res. 28:982009. View Article : Google Scholar : PubMed/NCBI
5	Markowska AI, Jefferies KC and Panjwani N: Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem. 286:29913–29921. 2011. View Article : Google Scholar : PubMed/NCBI
6	Punt S, Thijssen VL, Vrolijk J, de Kroon CD, Gorter A and Jordanova ES: Galectin-1, −3 and −9 expression and clinical significance in squamous cervical cancer. PLoS One. 10:e01291192015. View Article : Google Scholar : PubMed/NCBI
7	Ebrahim AH, Alalawi Z, Mirandola L, Rakhshanda R, Dahlbeck S, Nguyen D, Jenkins M, Grizzi F, Cobos E, Figueroa JA, et al: Galectins in cancer: Carcinogenesis, diagnosis and therapy. Ann Transl Med. 2:882014.PubMed/NCBI
8	Liu X, Yang WT and Zheng PS: Msi1 promotes tumor growth and cell proliferation by targeting cell cycle checkpoint proteins p21, p27 and p53 in cervical carcinomas. Oncotarget. 5:10870–10885. 2014. View Article : Google Scholar : PubMed/NCBI
9	Pavlides SC, Huang KT, Reid DA, Wu L, Blank SV, Mittal K, Guo L, Rothenberg E, Rueda B, Cardozo T, et al: Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: Therapeutic potential for endometrial cancer. Endocrinology. 154:4030–4045. 2013. View Article : Google Scholar : PubMed/NCBI
10	Wu XL and Zheng PS: Undifferentiated embryonic cell transcription factor-1 (UTF1) inhibits the growth of cervical cancer cells by transactivating p27Kip1. Carcinogenesis. 34:1660–1668. 2013. View Article : Google Scholar : PubMed/NCBI
11	Kovak MR, Saraswati S, Schoen DJ and Diekman AB: Investigation of galectin-3 function in the reproductive tract by identification of binding ligands in human seminal plasma. Am J Reprod Immunol. 72:403–412. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhao Q, Guo X, Nash GB, Stone PC, Hilkens J, Rhodes JM and Yu LG: Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res. 69:6799–6806. 2009. View Article : Google Scholar : PubMed/NCBI
13	Oka N, Nakahara S, Takenaka Y, Fukumori T, Hogan V, Kanayama HO, Yanagawa T and Raz A: Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res. 65:7546–7553. 2005. View Article : Google Scholar : PubMed/NCBI
14	Peng W, Wang HY, Miyahara Y, Peng G and Wang RF: Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res. 68:7228–7236. 2008. View Article : Google Scholar : PubMed/NCBI
15	Wang W, Guo H, Geng J, Zheng X, Wei H, Sun R and Tian Z: Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack. J Biol Chem. 289:33311–33319. 2014. View Article : Google Scholar : PubMed/NCBI
16	Mitsuhashi A, Suzuka K, Yamazawa K, Matsui H, Seki K and Sekiya S: Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer. 103:724–730. 2005. View Article : Google Scholar : PubMed/NCBI
17	Cui N, Yang WT and Zheng PS: Slug inhibits the proliferation and tumor formation of human cervical cancer cells by up-regulating the p21/p27 proteins and down-regulating the activity of the Wnt/β-catenin signaling pathway via the trans-suppression Akt1/p-Akt1 expression. Oncotarget. 7:26152–26167. 2016. View Article : Google Scholar : PubMed/NCBI
18	Huang K-T, Pavlides SC, Lecanda J, Blank SV, Mittal KR and Gold LI: Estrogen and progesterone regulate p27kip1 levels via the ubiquitin-proteasome system: Pathogenic and therapeutic implications for endometrial cancer. PLoS One. 7:e460722012. View Article : Google Scholar : PubMed/NCBI
19	Zhou N, Yuan S, Wang R, Zhang W and Chen JJ: Role of dual specificity tyrosine-phosphorylation-regulated kinase 1B (Dyrk1B) in S-phase entry of HPV E7 expressing cells from quiescence. Oncotarget. 6:30745–30761. 2015. View Article : Google Scholar : PubMed/NCBI
20	Rath SL and Senapati S: Mechanism of p27 unfolding for CDK2 reactivation. Sci Rep. 6:264502016. View Article : Google Scholar : PubMed/NCBI